Cancer

News

Pandemic and currency headwinds hurt Roche in first half

Roche has announced half-year results showing the COVID-19 pandemic affected sales of its key products, with currency headwinds also weighing on revenues.

News

Merck KGaA takes second option from cancer immunotherapy pac...

Germany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics.

News

NICE backs NHS use for Astellas' Xospata after rethink

NICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia

News

FDA experts okay GSK's multiple myeloma drug despite safety ...

GlaxoSmithKline’s potential first-in-class multiple myeloma drug belantamab mafodotin has taken a step closer to US approval after unanimous backing from a panel of expert advisers convened

News

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

A cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery.

Views & Analysis

Helping HCPs navigate the ever-evolving advanced cancer land...

OPEN Health’s Christine Drewienkiewicz, Sara Black and Annie Rankin on advances in modern oncology and how pharma can help ensure maximum patient benefit

Pandemic and currency headwinds hurt Roche in first half

Merck KGaA takes second option from cancer immunotherapy pac...

NICE backs NHS use for Astellas' Xospata after rethink

FDA experts okay GSK's multiple myeloma drug despite safety ...

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

Helping HCPs navigate the ever-evolving advanced cancer land...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Cancer

Editor's Picks